Agonistas de la trombopoyetina como manejo farmacológico de la trombocitopenia inmune primaria

Abstract

Primary Immune Thrombocytopenia is an autoimmune hematological disease that is distinguished by having platelets in a number less than 100,000, which causes clinical manifestations in patients such as the presence of ecchymosis, petechiae and even massive hemorrhages that can compromise the patient's life. For its diagnosis, other complementary tests are carried out, since it is a pathology in which there is no standard or specific test to diagnose it, and therefore its diagnosis is made by exclusion; and its treatment is first, second or third line will depend on the number of platelets and the phase of the disease, thrombopoietin agonists standing out over other drugs in the management of chronic or refractory Primary Immune Thrombocytopenia. Describing the pharmacological management of Primary Immune Thrombocytopenia through the administration of thrombopoietin agonists is essential, since through it it will be possible to demonstrate all the patients who benefit from this drug as well as its efficacy and the appearance of adverse effects. It is expected to find that thrombopoietin agonists are effective and safe drugs in the treatment of Primary Immune Thrombocytopenia, although being a safe pharmacological treatment, the risk-benefit must always be assessed in patients suffering from Primary Immune Thrombocytopenia. since through it it will be possible to demonstrate all the patients who benefit from this drug as well as its efficacy and the appearance of adverse effects. It is expected to find that thrombopoietin agonists are effective and safe drugs in the treatment of Primary Immune Thrombocytopenia, although being a safe pharmacological treatment, the risk-benefit must always be assessed in patients suffering from Primary Immune Thrombocytopenia. since through it it will be possible to demonstrate all the patients who benefit from this drug as well as its efficacy and the appearance of adverse effects. It is expected to find that thrombopoietin agonists are effective and safe drugs in the treatment of Primary Immune Thrombocytopenia, although being a safe pharmacological treatment, the risk-benefit must always be assessed in patients suffering from Primary Immune Thrombocytopenia.